TP53 and cancer: On the basis of SIENDO trial results presented at the ASCO meeting in June 2023 (in TP53 wild-type EC patients, selinexor delayed cancer growth for a median of 27.4 months versus 5.2 months with placebo), the X-PORT 042 trial is now ongoing—a phase III trial of selinexor including p53 wt advanced/metastatic EC.